For most of the last thirty years, Alzheimer’s research was a story of promising theories and failed trials. In the last few years, that story has genuinely changed. There is still no cure — and anyone promising one should be met with skepticism — but for the first time, families have disease-modifying treatments, dramatically better diagnostic tools, and strong evidence that lifestyle changes help. Here’s a plain-language tour of where things stand.

The first treatments that slow the disease

Two FDA-approved therapies — lecanemab (brand name Leqembi) and donanemab (Kisunla) — target amyloid, the sticky protein that builds up in the brains of people with Alzheimer’s. In clinical trials, both modestly slowed cognitive decline in people with early-stage disease. “Modestly” is the honest word: these drugs slow the disease by months, not years, and they don’t restore lost abilities.

They also come with real considerations. They’re given by infusion, they require regular brain imaging to monitor for a side effect called ARIA (small areas of brain swelling or bleeding), and they only work in the early stages — one more reason early diagnosis matters. For the right patient at the right time, though, they represent something the field has never had before: treatments that change the course of the disease rather than just easing symptoms.

Diagnosis is getting dramatically easier

Until recently, confirming Alzheimer’s required a PET scan or a spinal tap — expensive, invasive, and hard to access. That is changing quickly. Blood tests that measure proteins like p-tau217 can now detect Alzheimer’s-related changes with accuracy approaching those gold-standard methods, and the FDA cleared the first such blood test for clinical use in 2025.

Why this matters for families: earlier, cheaper, more accessible diagnosis — potentially from a primary care office rather than a specialty memory clinic with a six-month waitlist. It also accelerates research itself, making it faster to identify participants for clinical trials.

The strongest evidence yet for lifestyle

In 2025, results from the landmark U.S. POINTER study — a large, multi-site trial of older adults at risk for cognitive decline — showed that a structured program of exercise, healthy diet, cognitive and social engagement, and health monitoring measurably improved cognitive performance compared to a lower-intensity approach. It confirmed what smaller studies had long suggested: while lifestyle can’t prevent Alzheimer’s outright, what’s good for the heart is genuinely good for the brain, at any age.

What’s coming next

The research pipeline is broader than it has ever been. Scientists are testing therapies that target tau (the other hallmark Alzheimer’s protein), drugs aimed at brain inflammation, and repurposed medications — including large trials of GLP-1 drugs originally developed for diabetes. Not all of these will pan out; most experimental treatments don’t. But the field is no longer betting on a single theory, and each result sharpens the picture.

What this means for your family

Three practical takeaways. First, if you’re noticing changes in a loved one, seek evaluation early — the newest treatments only help in the earliest stages. Second, be wary of anything marketed as a cure or “reversal”; real progress is happening, and it doesn’t look like miracle headlines. Third, whatever the stage, excellent daily care — engagement, nutrition, routine, dignity — remains the most powerful therapy available, and it’s available right now.